Do we need a different set of response assessment criteria for tumor immunotherapy?

Antoni Ribas; Bartosz Chmielowski; John A Glaspy

doi:10.1158/1078-0432.CCR-09-2376

Do we need a different set of response assessment criteria for tumor immunotherapy?

Clin Cancer Res. 2009 Dec 1;15(23):7116-8. doi: 10.1158/1078-0432.CCR-09-2376. Epub 2009 Nov 24.

Authors

Antoni Ribas¹, Bartosz Chmielowski, John A Glaspy

Affiliation

¹ Department of Medicine, Division of Hematology/Oncology, University of California, Los Angeles, Los Angeles, California 90095-1782, USA. aribas@mednet.ucla.edu

PMID: 19934296
DOI: 10.1158/1078-0432.CCR-09-2376

Abstract

Tumor shrinkage induced by tumor immunotherapy may be preceded by inflammatory changes. This confounds the assessment of response rates to tumor immunotherapy. In this issue of Clinical Cancer Research, Wolchok et al. attempt to address this peculiarity by proposing a new set of criteria termed immune-related response criteria.

Publication types

Comment

MeSH terms

Antibodies, Monoclonal / pharmacology
Clinical Trials, Phase II as Topic
Humans
Immunotherapy / methods*
Inflammation / pathology
Ipilimumab
Medical Oncology / standards
Models, Biological
Neoplasm Metastasis
Neoplasms / immunology
Neoplasms / therapy*
Randomized Controlled Trials as Topic
Treatment Outcome*

Substances

Antibodies, Monoclonal
Ipilimumab